Lead candidate for the treatment of chronic pain

Neuropathic pain therapy point by point

OUR LEAD MOLECULE PN6047 has the ability to become a medicine for the treatment of chronic pain. This is underpinned by the following:

PN6047 is a novel fully patented molecule without any significant toxic effects in preclinical testing. PN6047 can be cost effectively synthesized
PN6047 is highly selective for the delta opioid receptor and does not interact with other receptors, transporters or enzymes studied
PN6047 preferentially signals via Gi proteins compared with arrestin proteins
PN6047 has high potency and efficacy in reducing neuropathic pain in various animal models
PN6047 lacks unwanted morphine-like side-effects, such as analgesic tolerance, drug abuse potential and respiratory depression
PN6047 has an excellent preclinical safety profile lacking CVS/GIT interactions and seizure induction
PN6047 shows no histopathological effects following long-term multiple high dose administration.

THUS, PN6047 can be the drug of choice to combat neuropathic pain and other conditions involving sensory hypersensitivity such as chronic cough and itch.

PN6047 versus conventional

The advantages of PN6047, versus current neuropathic pain medicines are potentially substantial.

vs Conventional Opioids:
Better efficacy in sensory hypersensitivity disorders; no μ-opioids receptor side effects; no analgesic tolerance; no abuse potential.

vs Gabapentin:
No dose adjustment in renal insufficiency patients; no abuse potential; no cytochrome enzyme inhibition so less drug interactions.

vs Amitriptyline:
No cardiovascular complications; lower metabolite exposure; no dose adjustment in hepatic insufficiency patients; no significant food or drug interactions.

Latest news

View all

April 17, 2026

Watch PharmNovo at LSX in Lisbon

Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.

April 9, 2026

Capsules ready for Phase IIa Study

PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.

January 30, 2026

Welcome on Board

As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.

November 26, 2025

Endowed Chair awarded

We are delighted to share that Professor Amynah Pradhan has been awarded a prestigious Endowed Chair at Washington University, where she now serves as the Russell D. and Mary B. Shelden Professor of Anesthesiology.